PRDM16 and lung adenocarcinoma: Additionally, GNLY, HOXB7, MRPL33, and PRDM16 were upregulated in bladder urothelial carcinoma, colon adenocarcinoma, lung adenocarcinoma, and rectum adenocarcinoma based on the results of eRic validation (Figure S5; Table S1).